DDI2 and colorectal carcinoma: These observations are consistent with observations showing increased susceptibility to proteasome inhibition upon expression of a defective DDI2 protein in the colorectal carcinoma cell line, HCT116 [31], or upon DDI2 deficiency in the triple-negative breast cancer cell line, MDA-MB-231 [20].